Aller au contenu
Nutrition et métabolismeMéta-analyse d’essais3 min read

Diabetes self-management apps were linked to a 0.48% lower HbA1c across 12 trials

Collectif éditorial MoveVitals · Study published · Reading updated

Original paper:Mobile App-Based Interventions to Support Diabetes Self-Management: A Systematic Review of Randomized Controlled Trials to Identify Functions Associated with Glycemic Efficacy. · JMIR mHealth and uHealth · 2017 · Article original ↗

À retenir

Pooling 12 randomized trials with 974 adults with diabetes, app-based interventions lowered HbA1c by 0.48% (95% CI 0.19% to 0.77%) compared with usual care alone, without excess adverse events. The feature comparisons were exploratory subgroup analyses across few trials, so they point to hypotheses rather than proven app designs.

Study design

Méta-analyse d’essais

Reading basis

Published abstract

Reading focus

Design & applicability

Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.

Question de recherche

Diabetes apps differ widely in what they do, and nobody had a standard way to classify those functions or to say which ones help blood sugar. The authors built a classification of app functions, then asked how much apps lower HbA1c and which functions go with bigger drops.

Population et méthode

Systematic review and random-effects meta-analysis. The authors first built a three-axis taxonomy (clinical modules, functional modules, and functions with risk assessments) and validated it by classifying commercial diabetes apps. They searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, the Chinese Biomedical Literature Database and ClinicalTrials.gov from January 2007 to May 2016 for randomized trials in adult outpatients with diabetes comparing an app-based intervention with usual care alone. Mean differences in HbA1c and risk ratios for adverse events were pooled, followed by exploratory subgroup analyses by presence or absence of each module.

Résultats

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    Across 12 trials with 974 participants, apps were associated with an HbA1c reduction of 0.48% (95% CI 0.19% to 0.77%) with no excess adverse events.
  2. 2
    The reduction was larger in type 2 diabetes (0.67%, 95% CI 0.30% to 1.03%) than in type 1 diabetes (0.36%, 95% CI 0.08% to 0.81%).
  3. 3
    Apps with a complication prevention module showed a larger reduction (1.31%, 95% CI 0.66% to 1.96%) than those without (0.38%, 95% CI 0.09% to 0.67%; intersubgroup P=.01). A structured display also went with larger reductions (0.69% vs 0.16%; P=.03).
  4. 4
    A clinical decision-making function was not associated with a larger reduction (0.18% with vs 0.61% without; P=.10).

Limites et incertitude

  1. 1
    Only 12 trials, so each subgroup comparison rests on a handful of studies and several confidence intervals are wide.
  2. 2
    The module comparisons were exploratory and not randomized; apps that had one module often differed in other ways, so the module may not be the cause.
  3. 3
    Some printed intervals look inconsistent with their point estimates (for example, 0.16% with a lower bound of 0.16%), so the subgroup numbers should be read cautiously.
  4. 4
    Based on the abstract only; trial quality, follow-up length and heterogeneity are not reported.

Mise en perspective

On average, apps used alongside usual care were associated with a modest drop in HbA1c, and the signal was stronger in type 2 diabetes. The finding does not tell you which app to pick or that an app can replace care; talk with your diabetes team about any change to your management.

Vos données

If you log glucose, meals or medication in an app, the useful comparison is your own HbA1c or glucose trend over months, using the same meter or CGM and similar conditions. Single readings swing too much to judge an app.

Comprendre ce type de preuve

Pooling trials can improve precision, but compare populations, controls, bias and uncertainty. Network rankings include indirect evidence and do not identify a universal best treatment.

Résumé structuré des auteurs English

Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.

Background

Mobile health apps for diabetes self-management have different functions. However, the efficacy and safety of each function are not well studied, and no classification is available for these functions.

Objective

The aims of this study were to (1) develop and validate a taxonomy of apps for diabetes self-management, (2) investigate the glycemic efficacy of mobile app-based interventions among adults with diabetes in a systematic review of randomized controlled trials (RCTs), and (3) explore the contribution of different function to the effectiveness of entire app-based interventions using the taxonomy.

Methods

We developed a 3-axis taxonomy with columns of clinical modules, rows of functional modules and cells of functions with risk assessments. This taxonomy was validated by reviewing and classifying commercially available diabetes apps. We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, the Chinese Biomedical Literature Database, and ClinicalTrials.gov from January 2007 to May 2016. We included RCTs of adult outpatients with diabetes that compared using mobile app-based interventions with usual care alone. The mean differences (MDs) in hemoglobin A_(1c) (HbA_(1c)) concentrations and risk ratios of adverse events were pooled using a random-effects meta-analysis. After taxonomic classification, we performed exploratory subgroup analyses of the presence or absence of each module across the included app-based interventions.

Results

Across 12 included trials involving 974 participants, using app-based interventions was associated with a clinically significant reduction of HbA_(1c) (MD 0.48%, 95% CI 0.19%-0.77%) without excess adverse events. Larger HbA_(1c) reductions were noted among patients with type 2 diabetes than those with type 1 diabetes (MD 0.67%, 95% CI 0.30%-1.03% vs MD 0.36%, 95% CI 0.08%-0.81%). Having a complication prevention module in app-based interventions was associated with a greater HbA_(1c) reduction (with complication prevention: MD 1.31%, 95% CI 0.66%-1.96% vs without: MD 0.38%, 95% CI 0.09%-0.67%; intersubgroup P=.01), as was having a structured display (with structured display: MD 0.69%, 95% CI 0.32%-1.06% vs without: MD 0.16%, 95% CI 0.16%-0.48%; intersubgroup P=.03). However, having a clinical decision-making function was not associated with a larger HbA_(1c) reduction (with clinical decision making: MD 0.18%, 95% CI 0.21%-0.56% vs without: MD 0.61%, 95% CI 0.27%-0.95%; intersubgroup P=.10).

Conclusions

The use of mobile app-based interventions yields a clinically significant HbA_(1c) reduction among adult outpatients with diabetes, especially among those with type 2 diabetes. Our study suggests that the clinical decision-making function needs further improvement and evaluation before being added to apps.

Sources et attribution

Mobile App-Based Interventions to Support Diabetes Self-Management: A Systematic Review of Randomized Controlled Trials to Identify Functions Associated with Glycemic Efficacy.

Wu Y, Yao X, Vespasiani G, Nicolucci A, Dong Y, Kwong J, Li L, Sun X, Tian H, Li S.

JMIR mHealth and uHealth · 2017-03-14

DOI: 10.2196/mhealth.6522 ↗PubMed · 28292740 ↗Europe PMC · Licence indiquée: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée

Sources vérifiées 2026-11-01

Guides pratiques

À lire ensemble

·Méta-analyse d’essais

Early time-restricted eating linked to more weight loss and lower insulin than late eating

Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.

BMJ Medicine

Explications approfondiesLire l’étude →
·Essai randomisé

An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss

Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.

The New England Journal of Medicine

Explications approfondiesLire l’étude →
·Essai randomisé

In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain

In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.

Cell Metabolism

Explications approfondiesLire l’étude →
·Essai randomisé

Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)

Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.

The New England Journal of Medicine

Explications approfondiesLire l’étude →
Nutrition et métabolisme →